Market News AIOpen the app

Marker Therapeutics got a $16.2 million grant to help study its therapy MT-601 for lymphoma patients.

DealRead the original at SEC EDGAR
Good for MRKR

Marker won a $16.2 million grant for its planned MT-601 Phase 2 study, giving it outside funding without issuing shares. This supports development, but earlier encouraging results came from only 12 patients, and Phase 2 results are still ahead.

MRKR · Marker Therapeutics, Inc.

AI read · Good for MRKR

The AI's read

The grant gives Marker outside money to advance MT-601 without issuing shares. That can help pay for its next study. Earlier results showed responses, but they came from only 12 patients. The planned Phase 2 study has yet to confirm those results.

Get alerts for MRKR

Follow Marker Therapeutics, Inc. (MRKR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MRKR
Free on the App Store and Google Play, or on the web.